Literature DB >> 23517479

Orally active opioid compounds from a non-poppy source.

Robert B Raffa1, Jaclyn R Beckett, Vivek N Brahmbhatt, Theresa M Ebinger, Chrisjon A Fabian, Justin R Nixon, Steven T Orlando, Chintan A Rana, Ali H Tejani, Robert J Tomazic.   

Abstract

The basic science and clinical use of morphine and other "opioid" drugs are based almost exclusively on the extracts or analogues of compounds isolated from a single source, the opium poppy (Papaver somniferum). However, it now appears that biological diversity has evolved an alternative source. Specifically, at least two alkaloids isolated from the plant Mitragyna speciosa, mitragynine ((E)-2-[(2S,3S)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[3,2-h]quinolizin-2-yl]-3-methoxyprop-2-enoic acid methyl ester; 9-methoxy coryantheidine; MG) and 7-hydroxymitragynine (7-OH-MG), and several synthetic analogues of these natural products display centrally mediated (supraspinal and spinal) antinociceptive (analgesic) activity in various pain models. Several characteristics of these compounds suggest a classic "opioid" mechanism of action: nanomolar affinity for opioid receptors, competitive interaction with the opioid receptor antagonist naloxone, and two-way analgesic cross-tolerance with morphine. However, other characteristics of the compounds suggest novelty, particularly chemical structure and possible greater separation from side effects. We review the chemical and pharmacological properties of these compounds.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23517479     DOI: 10.1021/jm400143z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Mitragyna speciosa: Balancing Potential Medical Benefits and Abuse.

Authors:  Genevieve M Halpenny
Journal:  ACS Med Chem Lett       Date:  2017-08-08       Impact factor: 4.345

2.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.

Authors:  Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2016-05-18       Impact factor: 15.419

3.  Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice.

Authors:  Kenjiro Matsumoto; Minoru Narita; Naotaka Muramatsu; Terumi Nakayama; Kaori Misawa; Mariko Kitajima; Kimihito Tashima; Lakshmi A Devi; Tsutomu Suzuki; Hiromitsu Takayama; Syunji Horie
Journal:  J Pharmacol Exp Ther       Date:  2013-12-17       Impact factor: 4.030

Review 4.  Mitragyna Species as Pharmacological Agents: From Abuse to Promising Pharmaceutical Products.

Authors:  Islamudin Ahmad; Wisnu Cahyo Prabowo; Muhammad Arifuddin; Jaka Fadraersada; Niken Indriyanti; Herman Herman; Reza Yuridian Purwoko; Firzan Nainu; Anton Rahmadi; Swandari Paramita; Hadi Kuncoro; Nur Mita; Angga Cipta Narsa; Fajar Prasetya; Arsyik Ibrahim; Laode Rijai; Gemini Alam; Abdul Mun'im; Sukanya Dej-Adisai
Journal:  Life (Basel)       Date:  2022-01-27

5.  Kratom alkaloid mitragynine: Inhibition of chemotherapy-induced peripheral neuropathy in mice is dependent on sex and active adrenergic and opioid receptors.

Authors:  Daniel J Farkas; Jeffery D Foss; Sara Jane Ward; Scott M Rawls
Journal:  IBRO Neurosci Rep       Date:  2022-08-30

Review 6.  Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.

Authors:  Soumen Chakraborty; Susruta Majumdar
Journal:  Biochemistry       Date:  2020-09-22       Impact factor: 3.162

7.  Kratom pharmacology: Clues from planarians exposed to mitragynine.

Authors:  Sarah Uddin; Sonita Wiah; Tony Kim; Mia N Watson; Tyra Jennings; Scott M Rawls
Journal:  Physiol Behav       Date:  2021-06-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.